DDInter385 DDInter1435
In many countries (including Canada) cisapride has been either withdrawn or has had its indications limited due to reports about long QT syndrome due to cisapride, which predisposes to arrhythmias. The FDA issued a warning letter regarding this risk to health care professionals and patients.
Pexidartinib is a selective tyrosine kinase inhibitor that works by inhibiting the colony-stimulating factor (CSF1)/CSF1 receptor pathway. Pexidartinib was originally developed by Daiichi Sankyo, Inc. and it was approved by the FDA in August 2019 as the first systemic therapy for adult patients with symptomatic tenosynovial giant cell tumor. Tenosynovial giant cell tumor is a rare form of non-malignant tumor that causes the synovium and tendon sheaths to thicken and overgrow, leading to damage in surrounding joint tissue.[A182240,L7901] Debilitating symptoms often follow with tenosynovial giant cell tumors, along with a risk of significant functional limitations and a reduced quality of life in patients. While surgical resection is a current standard of care for tenosynovial giant cell tumor, there are tumor types where surgeries are deemed clinically ineffective with a high risk of lifetime recurrence. Pexidartinib works by blocking the immune responses that are activated in tenosynovial giant cell tumors. In clinical trials, pexidartinib was shown to promote improvements in patient symptoms and functional outcomes in TGCT. Pexidartinib is available in oral formulations and it is commonly marketed as Turalio.
Cisapride {u} (Compound) resembles {v} (Compound) Metoclopramide
Cisapride {u} may lead to a major life threatening interaction when taken with {v} Iloperidone
Cisapride {u} (Compound) binds {v} (Gene) HTR2B
Cisapride {u} (Compound) upregulates {v} (Gene) PAK1
Cisapride {u} (Compound) downregulates {v} (Gene) PUF60
Cisapride {u} may cause a minor interaction that can limit clinical effects when taken with {v} Sulfamethoxazole
Cisapride {u} may cause a minor interaction that can limit clinical effects when taken with {v} Morphine
Cisapride {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Nevirapine
Cisapride {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Erdafitinib
Cisapride {u} may lead to a major life threatening interaction when taken with {v} Haloperidol
Cisapride (Compound) resembles Metoclopramide (Compound)
Cisapride may lead to a major life threatening interaction when taken with Iloperidone
Cisapride (Compound) binds HTR2B (Gene)
Cisapride (Compound) upregulates PAK1 (Gene)
Cisapride (Compound) downregulates PUF60 (Gene)
Cisapride may cause a minor interaction that can limit clinical effects when taken with Sulfamethoxazole
Cisapride may cause a minor interaction that can limit clinical effects when taken with Morphine
Cisapride may cause a moderate interaction that could exacerbate diseases when taken with Nevirapine
Cisapride may cause a moderate interaction that could exacerbate diseases when taken with Erdafitinib
Cisapride may lead to a major life threatening interaction when taken with Haloperidol